Core Viewpoint - The pharmaceutical and medical stocks experienced significant fluctuations, with several companies facing notable declines in their stock prices [2] Group 1: Stock Performance - Bibet fell nearly 15% [2] - Companies such as Baipusais, Zhijiang Biology, Wanfubio, Hualan Vaccine, Yongshun Biology, Hongbo Pharmaceutical, and Nearshore Protein saw declines exceeding 5% [2]

Group 1 - The core point of the news is that Bibeite experienced a decline in stock price and trading volume on January 27, with a drop of 2.37% and a total transaction amount of 214 million yuan [1] - On January 27, Bibeite had a financing buy amount of 21.59 million yuan, with a net financing purchase of 4.36 million yuan after repaying 17.22 million yuan [1][2] - As of January 27, the total balance of margin trading for Bibeite was 155 million yuan, which represents 6.23% of its circulating market value [2] Group 2 - Bibeite, established on January 19, 2012, is located in the Guangzhou High-tech Industrial Development Zone and focuses on the independent research and development of innovative drugs [2] - As of January 20, the number of shareholders for Bibeite was 13,000, a decrease of 7.87% from the previous period, while the average circulating shares per person increased by 8.55% to 3,560 shares [2] - For the period from January to September 2025, Bibeite reported zero revenue and a net loss attributable to shareholders of 107 million yuan [2]

中国经济网北京1月26日讯 必贝特(688759.SH)近日发布2025年年度业绩预亏公告。 经财务部门初步测算，必贝特预计2025年年度实现归属于母公司所有者的净利润与上年同期（法定披露 数据）相比，将出现亏损，实现归属于母公司所有者的净利润为-16,600万元到-13,600万元；归属于母 公司所有者扣除非经常性损益后的净利润-18,800万元到-15,800万元。本次业绩预告情况未经注册会计 师审计。 2022年至2024年，必贝特均无营业收入，净利润/归属于普通股股东的净利润分别为-18,833.88万 元、-17,275.51万元、-5,599.83万元；扣除非经常性损益后归属于普通股股东的净利润分别为-20,749.04 万元、-18,776.76万元、-15,804.87万元；经营活动产生的现金流量净额分别为-12,766.89万 元、-12,737.30万元、-8,961.35万元。 必贝特于2025年10月28日在上交所科创板上市，发行股票数量9,000.0000万股，发行价格为17.78元/ 股，保荐机构（主承销商）为中信证券股份有限公司，保荐代表人为彭浏用、熊志兵，联席主承销商为 国信证 ...

1月26日，必贝特涨5.02%，截至发稿，报57.08元/股，成交7102.99万元，换手率2.78%，总市值256.88 亿元。 资料显示，广州必贝特医药股份有限公司位于广东省广州市高新技术产业开发区科学城崖鹰石路25号 A-3栋第七层、第八层，成立日期2012年1月19日，上市日期2025年10月28日，公司主营业务涉及创新 药自主研发。 截至发稿，李俊累计任职时间8年49天，现任基金资产总规模956.67亿元，任职期间最佳基金回报 146.12%， 任职期间最差基金回报-39.56%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，任何在本文出现的信息（包括但 不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验，因此本文内 容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 数据显示，华夏基金旗下1只基金重仓必贝特。华夏中证光伏产业ETF发起式联接A（012885）四季度持 ...

北京商报讯（记者 丁宁）1月23日晚间，必贝特（688759）发布2025年年度业绩预亏公告显示，经财务 部门初步测算，预计2025年年度实现归属净利润与上年同期（法定披露数据）相比，将出现亏损，实现 归属净利润为-1.36亿元至-1.66亿元。 必贝特表示，报告期内，公司尚未实现营业收入，与经营相关的研发投入和运营支出等持续发生。公司 共有1款产品获批上市，1款产品处于III期临床试验阶段，1款产品已获准开展III期临床试验，5款产品处 于I期临床试验阶段，另有多款产品处于临床前研究阶段。因公司尚未实现营业收入并保持较高的研发 投入，预计2025年度将出现亏损。 ...

证券日报网讯1月23日，必贝特在互动平台回答投资者提问时表示，截至2026年1月20日，公司股东人数 为13048户。 ...

Group 1 - The chemical pharmaceutical sector increased by 0.91% on January 23, with Guangshantang leading the gains [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] - Guangshantang's stock price rose by 20.00% to 96.28, with a trading volume of 185,500 shares [1] Group 2 - The main funds in the chemical pharmaceutical sector experienced a net outflow of 487 million yuan, while retail investors saw a net inflow of 1.12 billion yuan [2] - The stock performance of several companies showed varied results, with some experiencing declines, such as Xingqi Eye Medicine down 4.86% [2] - The trading volume and turnover for various companies in the sector were significant, with notable figures such as 1.62 billion yuan for Xingqi Eye Medicine [2] Group 3 - Guangshantang had a net inflow of 396 million yuan from main funds, while retail investors had a net outflow of 136 million yuan [3] - Other companies like Hancheng Group and Shutaishen also showed significant net inflows and outflows, indicating varied investor sentiment [3] - The data reflects a mixed investment environment within the chemical pharmaceutical sector, with both institutional and retail investors actively participating [3]

证券代码：688759 证券简称：必贝特 公告编号：2026-002 广州必贝特医药股份有限公司 2025 年年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （二）业绩预告情况 （1）经财务部门初步测算，预计 2025 年年度实现归属于母公司所有者的净 利润与上年同期（法定披露数据）相比，将出现亏损，实现归属于母公司所有者 的净利润为-16,600 万元到-13,600 万元。 （2）归属于母公司所有者扣除非经常性损益后的净利润-18,800 万元到 -15,800 万元。 （三）本次业绩预告情况未经注册会计师审计。 二、上年同期经营业绩和财务状况 （一）利润总额：-5,590.78 万元。归属于母公司所有者的净利润：-5,599.83 万元。归属于母公司所有者的扣除非经常性损益的净利润：-15,804.87 万元。 （二）每股收益：-0.16 元/股。 三、本期业绩预亏的主要原因 报告期内，公司尚未实现营业收入，与经营相关的研发投入和运营支出等持 续发生。公司共有 1 款产品获批上 ...

格隆汇1月23日丨必贝特(688759.SH)公布，经财务部门初步测算，预计2025年年度实现归属于母公司所 有者的净利润与上年同期（法定披露数据）相比，将出现亏损，实现归属于母公司所有者的净利润 为-16,600万元到-13,600万元；归属于母公司所有者扣除非经常性损益后的净利润-18,800万元到-15,800 万元。 ...

Group 1 - The core viewpoint of the news is that the A-share market is seeing a strong performance in innovative drug concept stocks, driven by a policy encouraging the sale of innovative drugs and reference preparations in retail pharmacies [1] Group 2 - Guangshentang (300436) experienced a 20% increase, with a total market value of 15.3 billion and a year-to-date increase of 8% [2] - Zhongsan Co. (301093) rose by 12%, with a market capitalization of 13.8 billion and a year-to-date increase of 63.89% [2] - Hanshang Group (600774) saw a 10% increase, with a market value of 3.408 billion and a year-to-date increase of 26.37% [2] - Hite Bio (300683) increased by 7.92%, with a market capitalization of 4.371 billion and a year-to-date increase of 20.41% [2] - Bibete (688759) rose by 6.64%, with a market value of 24.9 billion and a year-to-date increase of 90.09% [2] - Shutaishen (300204) increased by 5.78%, with a market capitalization of 13.6 billion and a year-to-date increase of 4.58% [2] - Chengdu Xian Dao (688222) rose by 5.42%, with a market value of 13.8 billion and a year-to-date increase of 46.78% [2] - Haiwang Bio (000078) increased by 5.23%, with a market capitalization of 10.1 billion and a year-to-date increase of 10.40% [2] - Jiuzhoutong (600998) rose by 4.71%, with a market value of 28 billion and a year-to-date increase of 8.59% [2] - Hongbo Pharmaceutical (301230) increased by 4.60%, with a market capitalization of 6.76 billion and a year-to-date increase of 62.48% [2] - Huana Pharmaceutical (688799) rose by 4.09%, with a market value of 6.882 billion and a year-to-date increase of 9.87% [2]